In this study, we showed that the inhibitory efficacy of MT-1303 on chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells was comparable to that of an anti-mTNF-α mAb, indicating that MT-1303 may have therapeutic potential for IBD. Here, CD4 is linked to inflammatory bowel disease.